Credit Suisse Group initiated coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Wednesday morning, MarketBeat reports. The firm issued an outperform rating and a $103.00 target price on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the stock. UBS Group set a $88.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a report on Wednesday. Stifel Nicolaus set a $105.00 target price on shares of Esperion Therapeutics and gave the company a buy rating in a report on Monday. BidaskClub upgraded shares of Esperion Therapeutics from a buy rating to a strong-buy rating in a report on Saturday, January 13th. Bank of America upgraded shares of Esperion Therapeutics from a neutral rating to a buy rating and set a $76.00 target price for the company in a report on Friday, January 5th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a buy rating to a strong-buy rating and raised their price target for the company from $72.00 to $81.00 in a research report on Thursday, December 14th. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $72.85.
Esperion Therapeutics (NASDAQ ESPR) traded down $0.88 during mid-day trading on Wednesday, hitting $74.96. 566,864 shares of the stock traded hands, compared to its average volume of 586,576. Esperion Therapeutics has a 1 year low of $10.71 and a 1 year high of $76.17. The stock has a market capitalization of $1,930.00, a price-to-earnings ratio of -10.93 and a beta of 2.73.
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) EPS. equities research analysts anticipate that Esperion Therapeutics will post -7.36 earnings per share for the current year.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the sale, the director now owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 32.50% of the company’s stock.
A number of large investors have recently bought and sold shares of ESPR. Meditor Group Ltd grew its position in Esperion Therapeutics by 305.5% in the 3rd quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock worth $115,022,000 after purchasing an additional 1,728,935 shares during the period. State Street Corp grew its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after purchasing an additional 1,093,292 shares during the period. Discovery Capital Management LLC CT grew its position in Esperion Therapeutics by 152.9% in the 2nd quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after purchasing an additional 583,529 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $12,583,000. Finally, BNP Paribas Arbitrage SA grew its position in Esperion Therapeutics by 12,603.4% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 201,476 shares of the biopharmaceutical company’s stock worth $10,098,000 after purchasing an additional 199,890 shares during the period. 92.35% of the stock is owned by institutional investors and hedge funds.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.